Balance Sheet

Accounts Payables Accumulated Depreciation Accumulated Expenses Assets Cash & Equivalents Common Equity Construction in Progress Current Assets Current Deferred Revenue Current Leases Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Liabilities from Discontinued Operations Liabilities from Discontinued Operations Loans - Net Loans - Net Long-Term Investments Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Non-Current Deffered Revenue Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Pension Preferred Shares Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Accured Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Treasury Shares Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Cost of Revenue Gross Profit Leases Long-Term Debt Repayments Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Preferred Shares Issued Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Accured Receivables - Net Receivables - Other Revenue - Other Shares Issued Shares Outstanding Shares Outstanding

Perspective Therapeutics (CATX) Receivables - Net (2016 - 2026)

Perspective Therapeutics' Receivables - Net history spans 16 years, with the latest figure at $58000.0 for Q1 2026.

On a quarterly basis, Receivables - Net fell 25.64% to $58000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $58000.0, a 25.64% decrease, with the full-year FY2025 number at $6000.0, down 94.83% from a year prior.
Receivables - Net hit $58000.0 in Q1 2026 for Perspective Therapeutics, up from $6000.0 in the prior quarter.
Over the last five years, Receivables - Net for CATX hit a ceiling of $2.1 million in Q1 2022 and a floor of $6000.0 in Q4 2025.
Historically, Receivables - Net has averaged $806882.4 across 5 years, with a median of $999000.0 in 2024.
The widest YoY moves for Receivables - Net: up 58.45% in 2025, down 94.83% in 2025.
Tracing CATX's Receivables - Net over 5 years: stood at $1.4 million in 2022, then fell by 14.53% to $1.2 million in 2023, then plummeted by 90.04% to $116000.0 in 2024, then tumbled by 94.83% to $6000.0 in 2025, then soared by 866.67% to $58000.0 in 2026.
Business Quant data shows Receivables - Net for CATX at $58000.0 in Q1 2026, $6000.0 in Q4 2025, and $179000.0 in Q3 2025.